Raymond James Financial
ADAP

Raymond James Financial’s Adaptimmune Therapeutics ADAP Stock Holding History

Raymond James Financial’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,261
Closed -$3.28K – 5159
2025
Q3 		$3.28K Hold
25,261
– – ﹤0.01% 4950
2025
Q2 		$6.05K Hold
25,261
– – ﹤0.01% 6103
2025
Q1 		$4.98K Sell
25,261
-5,820
-19% -$3.01K ﹤0.01% 4799
2024
Q4 		$16.7K Buy
+31,081
New +$22.6K ﹤0.01% 4744

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Raymond James Financial's ADAP Position: Q4 2025 in Review

Raymond James Financial sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 25,261 shares — an estimated $3.28K sold.

Raymond James Financial first reported a position in ADAP in Q4 2024 and held it in 4 quarters. The position peaked at $16.7K in Q4 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Raymond James Financial reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Raymond James Financial sold 25,261 Adaptimmune Therapeutics shares in Q4 2025, an estimated $3.28K.
  • Raymond James Financial first reported a position in Adaptimmune Therapeutics in Q4 2024 and held it in 4 quarters.
  • Raymond James Financial's Adaptimmune Therapeutics position peaked at $16.7K in Q4 2024.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Raymond James Financial's 13F filing for Q4 2025, filed 18 Feb 2026.